CCL5 and epilepsy: In support of the importance of CCL5 and its receptors for BBB regulation, animal studies of epilepsy demonstrated that antagonist-based inhibition of CCR5 on blood cells or blocking CCL5 can reduce BBB permeability and mitigate disease severity (35).